DAN SPIRA

Chief Executive Officer

Dan Spira was a former Vice President at Valeant Pharmaceuticals from 2011 to 2015. This included being based in Australia as the Managing Director of iNova Pharmaceuticals and Bausch + Lomb from 2011 to 2014 and then in North America with responsibility for a portfolio of Valeant owned companies.  Prior to that he spent 15 years at Johnson & Johnson in various roles including VP, Country Manager and Chief Marketing Officer.

Dan has now relocated back to Australia and returned as CEO of the iNova group.

Our regional leaders are responsible for all Sales, Marketing, Local Supply Chain and Regulatory functions within their countries

SACHA ERNST

President of Asia

Sacha has more than 16 years of healthcare industry experience in finance, corporate strategy and development, and general management spanning Asia, Europe and USA. This experience includes Vice President roles at DKSH managing the Vietnam and Myanmar markets. Prior to that, Sacha spent 14 years with Novartis including GM and Head of South Asia (with responsibility for 9 markets) as well as Director of Strategy, Business Development & Licencing for Developing Markets (Asia, Middle East, Africa and Russia)

KYM HAMPTON

Managing Director Africa

Kym has been leading the iNova South Africa business since 2013 and prior to that was in General Management positions at Adcock Ingram.

At a corporate level, we have the following functions ‘Centres of Excellence’ that support our country teams and also work on future business growth initiatives.

JOE BASILE

Chief Financial Officer

Joe joined iNova in 2013 as CFO for Australia and New Zealand and will now broaden his responsibilities to be CFO of the iNova group. Prior to iNova, Joe held CFO positions in Novartis both in Australia and also in Asia (Singapore and Thailand).

GEOFF RUDLAND

Chief Operating Officer

Between 2011-2015 Geoff was Supply Chain Director for the iNova group and also Valeant’s Asia Pacific and Africa head of Supply Chain. Before Valeant Geoff held senior supply chain and operations roles in Australia and Asia.

KATE MESSITER

General Counsel and Head of Communications

Kate joins us from Mundipharma where she has most recently been head of Legal & Compliance for their Australian business. Prior to Mundipharma, Kate was in senior legal roles at Novartis, Fairfax and was a lawyer at Mallesons.

ANDREW DAVIS

Chief Business Development / M&A Officer

Andrew was most recently head of Business Development for Merck’s oncology business and was previously head of Business Development / M&A at Valeant.

BLANE COULCHER

Executive Director- Strategy, People & Technology

Blane has held senior strategy and commercial roles across FMCG and Industrial Services companies including other PEP / Carlyle owned companies. He also has a consulting background through Bain & Company.

FILOMENA MAIESE

Executive Director- Portfolio Strategy & Innovation

Filomena is an experienced OTC and Pharma commercial leader with 25 year experience across organisations including Pfizer and Johnson & Johnson in senior roles such as Marketing Director and OTC Franchise leader. Filomena has a track record of success in building iconic brands and product pipeline across markets for major brands such as Zyrtec, Benadryl, Sudafed, Codral, Listerine and Nicorette. Her most recent role has been Director of Business Development & Marketing for ASMI (Australia Self Medicated Industry Association) where she has had the opportunity to have a seat at the table representing all of the key industry players as they drive and shape the future OTC market landscape.